lilly tirzepatide approval https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Tirzepatide shows 47% greater weight

Data from the SURPASS-4 trial indicated that patients using Tirzepatide experienced a significantly slower decline in eGFR compared to those on insulin glargine

Results Twenty-one experts on GERD formulated 30 clinical recommendations for appropriately indicating diagnostic tests for disease phenotypes and their medical treatment, refractory GERD management, endoscopic and surgical treatment indications, the control of GERD in obesity, pregnancy, and older adults, as well as the role of Helicobacter pylori infection and GLP-1 agonists

Are 1-Month Weight Loss Results the Same for Everyone

Providers should carefully screen candidates, counsel them on risks, and monitor for adverse events